[Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis]. / MS-taudin diagnoosi, lääkehoito ja kuntoutus.
Duodecim
; 126(2): 199-200, 2010.
Article
em Fi
| MEDLINE
| ID: mdl-20405605
ABSTRACT
Treatment is initiated when the McDonald criteria for relapsing-remitting multiple sclerosis (RRMS) are fulfilled. High-risk patients with clinically isolated syndrome are followed using magnetic resonance imaging for one year after the first imaging. Interferon-beta or glatiramer acetate are the first-line immunomodulating drugs (IMD) for RRMS. MxA protein is measured 12 and 24 months after initiation of Interferon-beta to evaluate possible development of neutralizing antibodies. If MxA protein may not be detected repeatedly interferon-beta treatment is discontinued. If the disease is active in spite of treatment with first-line IMD, natalizumab may be considered as a second-line therapy. IMD is stopped when the transition to secondary progressive phase has occurred (or upon transition to secondary progressive phase).
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Imunossupressores
/
Esclerose Múltipla
Tipo de estudo:
Diagnostic_studies
/
Guideline
Limite:
Humans
Idioma:
Fi
Ano de publicação:
2010
Tipo de documento:
Article